View ValuationFarmacosmo 향후 성장Future 기준 점검 4/6Farmacosmo은 연간 수입과 매출이 각각 75.5%와 7.9% 증가할 것으로 예상되고 EPS는 연간 61.9%만큼 증가할 것으로 예상됩니다.핵심 정보75.5%이익 성장률61.88%EPS 성장률Specialty Retail 이익 성장30.5%매출 성장률7.9%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트21 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Jun 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€1.4m). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (€19.1m market cap, or US$21.7m).Reported Earnings • Jun 10Full year 2025 earnings releasedFull year 2025 results: Revenue: €56.3m (down 12% from FY 2024). Net loss: €4.43m (loss widened 49% from FY 2024).공고 • Jun 09Farmacosmo S.p.A., Annual General Meeting, Jun 22, 2026Farmacosmo S.p.A., Annual General Meeting, Jun 22, 2026, at 08:00 W. Europe Standard Time.New Risk • May 24New major risk - Revenue and earnings growthEarnings have declined by 64% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€15.4m market cap, or US$17.9m).Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Diego Rossano was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Dec 31Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million.Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million on December 30, 2025. A cash consideration of €4 million will be paid by Pet Being. Pet Being will pay an earnout/contingent payment of €1.1 million cash. As part of consideration, €5.1 million is paid towards common equity of Bau Cosmesi. The transaction is subject to approval of offer by target shareholders. illimity Bank S.p.A. acted as financial advisor for Farmacosmo S.p.A. Lovells Studio Legale acted as legal advisor for Farmacosmo S.p.A. Gitti And Partners Studio Legale Associato acted as legal advisor for Pet Being. Italaudit SpA acted as due diligence provider for Pet Being.공고 • Dec 17Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million.Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million on December 15, 2025. A cash consideration of €1.8 million will be paid by Farmacosmo S.p.A. Farmacosmo S.p.A. will pay an earnout/contingent payment of €0.3 million cash. Upon completion, Farmacosmo S.p.A. will own 100% stake in Farmacia De Leo S.R.L. In related transaction Farmacia De Leo Srl sold the physical pharmacy business unit to Nica Sgroi Srl. The effectiveness of the transaction is subject to obtaining authorization for the transfer of the physical pharmacy from the competent authority.공고 • Apr 15Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025, at 08:00 W. Europe Standard Time.New Risk • Oct 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €3.9m Forecast net loss in 2 years: €206k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€206k net loss in 2 years). Market cap is less than US$100m (€26.5m market cap, or US$29.4m).New Risk • May 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€7.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€7.0m free cash flow). Earnings have declined by 72% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€1.0m net loss in 3 years). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€34.3m market cap, or US$36.6m).New Risk • Apr 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 31% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Earnings are forecast to decline by an average of 31% per year for the foreseeable future. Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€35.6m market cap, or US$38.2m).New Risk • Apr 24New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€35.2m market cap, or US$37.7m).New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.3% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€29.5m market cap, or US$31.0m).New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€38.0m market cap, or US$42.1m).Board Change • Feb 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Director Dorothy Rubeis was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Feb 04Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi.Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi on February 3, 2023.공고 • Jan 10Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi.Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.공고 • Nov 13Farmacosmo S.p.A. (BIT:COSMO) acquired a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson.Farmacosmo S.p.A. (BIT:COSMO) acquired a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson on November 11, 2022. Farmacosmo S.p.A. (BIT:COSMO) completed the acquisition of a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson on November 11, 2022.공고 • Aug 10Farmacosmo S.p.A. (BIT:COSMO) signed a binding agreement for the acquisition of 69.88% stake in VIN.CI. SRL from Vincenzo Cioffi.Farmacosmo S.p.A. (BIT:COSMO) signed a binding agreement for the acquisition of 69.88% stake in VIN.CI. SRL from Vincenzo Cioffi on August 9, 2022.Board Change • May 09Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.이익 및 매출 성장 예측DB:ZJ1 - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202855034212/31/202748-123212/31/202641-1-11212/31/202556-4-11N/A9/30/202558-5-3-1N/A6/30/202559-5-5-2N/A3/31/202562-4-4-2N/A12/31/202464-3-3-2N/A9/30/202466-3-2-1N/A6/30/202468-40-1N/A3/31/202470-4-3-3N/A12/31/202372-3-7-5N/A9/30/202372-2N/AN/AN/A6/30/202372-1N/AN/AN/A3/31/202369-1N/AN/AN/A12/31/202267-1N/AN/AN/A9/30/202266-1N/AN/AN/A6/30/2022640N/AN/AN/A3/31/2022610N/AN/AN/A12/31/2021580-10N/A9/30/2021561N/AN/AN/A12/31/202044012N/A12/31/2019240-1-1N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: ZJ1 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(1.9%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: ZJ1 (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: ZJ1 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: ZJ1 의 수익(연간 7.9%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: ZJ1 의 수익(연간 7.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: ZJ1의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YRetail 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/28 14:10종가2026/07/28 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Farmacosmo S.p.A.는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mattia PetraccaIntegrae SPATommaso MartinacciValueTrack
New Risk • Jun 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€1.4m). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (€19.1m market cap, or US$21.7m).
Reported Earnings • Jun 10Full year 2025 earnings releasedFull year 2025 results: Revenue: €56.3m (down 12% from FY 2024). Net loss: €4.43m (loss widened 49% from FY 2024).
공고 • Jun 09Farmacosmo S.p.A., Annual General Meeting, Jun 22, 2026Farmacosmo S.p.A., Annual General Meeting, Jun 22, 2026, at 08:00 W. Europe Standard Time.
New Risk • May 24New major risk - Revenue and earnings growthEarnings have declined by 64% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€15.4m market cap, or US$17.9m).
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Diego Rossano was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Dec 31Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million.Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million on December 30, 2025. A cash consideration of €4 million will be paid by Pet Being. Pet Being will pay an earnout/contingent payment of €1.1 million cash. As part of consideration, €5.1 million is paid towards common equity of Bau Cosmesi. The transaction is subject to approval of offer by target shareholders. illimity Bank S.p.A. acted as financial advisor for Farmacosmo S.p.A. Lovells Studio Legale acted as legal advisor for Farmacosmo S.p.A. Gitti And Partners Studio Legale Associato acted as legal advisor for Pet Being. Italaudit SpA acted as due diligence provider for Pet Being.
공고 • Dec 17Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million.Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million on December 15, 2025. A cash consideration of €1.8 million will be paid by Farmacosmo S.p.A. Farmacosmo S.p.A. will pay an earnout/contingent payment of €0.3 million cash. Upon completion, Farmacosmo S.p.A. will own 100% stake in Farmacia De Leo S.R.L. In related transaction Farmacia De Leo Srl sold the physical pharmacy business unit to Nica Sgroi Srl. The effectiveness of the transaction is subject to obtaining authorization for the transfer of the physical pharmacy from the competent authority.
공고 • Apr 15Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025, at 08:00 W. Europe Standard Time.
New Risk • Oct 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €3.9m Forecast net loss in 2 years: €206k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€206k net loss in 2 years). Market cap is less than US$100m (€26.5m market cap, or US$29.4m).
New Risk • May 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€7.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€7.0m free cash flow). Earnings have declined by 72% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€1.0m net loss in 3 years). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€34.3m market cap, or US$36.6m).
New Risk • Apr 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 31% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Earnings are forecast to decline by an average of 31% per year for the foreseeable future. Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€35.6m market cap, or US$38.2m).
New Risk • Apr 24New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€35.2m market cap, or US$37.7m).
New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.3% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€29.5m market cap, or US$31.0m).
New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€38.0m market cap, or US$42.1m).
Board Change • Feb 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Director Dorothy Rubeis was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Feb 04Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi.Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi on February 3, 2023.
공고 • Jan 10Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi.Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.
공고 • Nov 13Farmacosmo S.p.A. (BIT:COSMO) acquired a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson.Farmacosmo S.p.A. (BIT:COSMO) acquired a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson on November 11, 2022. Farmacosmo S.p.A. (BIT:COSMO) completed the acquisition of a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson on November 11, 2022.
공고 • Aug 10Farmacosmo S.p.A. (BIT:COSMO) signed a binding agreement for the acquisition of 69.88% stake in VIN.CI. SRL from Vincenzo Cioffi.Farmacosmo S.p.A. (BIT:COSMO) signed a binding agreement for the acquisition of 69.88% stake in VIN.CI. SRL from Vincenzo Cioffi on August 9, 2022.
Board Change • May 09Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.